Centessa Pharmaceuticals plc (NASDAQ:CNTA) Receives Average Recommendation of “Buy” from Analysts

Centessa Pharmaceuticals plc (NASDAQ:CNTA) has been given an average recommendation of “Buy” by the seven brokerages that are presently covering the stock, MarketBeat reports. Seven analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $26.00.

A number of research firms have recently issued reports on CNTA. TD Cowen began coverage on Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They issued a “buy” rating for the company. Guggenheim reaffirmed a “buy” rating on shares of Centessa Pharmaceuticals in a report on Monday, February 10th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $27.00 price objective on shares of Centessa Pharmaceuticals in a report on Friday, March 7th.

Insider Activity

In other Centessa Pharmaceuticals news, CEO Saurabh Saha sold 55,000 shares of the stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $17.44, for a total transaction of $959,200.00. Following the transaction, the chief executive officer now owns 520,661 shares in the company, valued at $9,080,327.84. This represents a 9.55 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CTO Tia L. Bush sold 11,000 shares of Centessa Pharmaceuticals stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $16.86, for a total value of $185,460.00. Following the completion of the transaction, the chief technology officer now directly owns 121,503 shares of the company’s stock, valued at $2,048,540.58. This represents a 8.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 260,168 shares of company stock valued at $4,357,818. 11.59% of the stock is owned by company insiders.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. Atria Investments Inc increased its stake in Centessa Pharmaceuticals by 7.0% in the third quarter. Atria Investments Inc now owns 17,134 shares of the company’s stock valued at $274,000 after purchasing an additional 1,116 shares in the last quarter. GSA Capital Partners LLP raised its stake in Centessa Pharmaceuticals by 66.1% during the 3rd quarter. GSA Capital Partners LLP now owns 93,658 shares of the company’s stock worth $1,498,000 after buying an additional 37,275 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in Centessa Pharmaceuticals by 88.1% in the third quarter. The Manufacturers Life Insurance Company now owns 264,969 shares of the company’s stock worth $4,237,000 after acquiring an additional 124,075 shares in the last quarter. FMR LLC grew its stake in Centessa Pharmaceuticals by 4.6% in the third quarter. FMR LLC now owns 2,916,494 shares of the company’s stock valued at $46,635,000 after acquiring an additional 129,300 shares during the period. Finally, Ally Bridge Group NY LLC bought a new stake in shares of Centessa Pharmaceuticals during the third quarter valued at approximately $4,951,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Centessa Pharmaceuticals Trading Up 1.6 %

Shares of NASDAQ:CNTA opened at $16.77 on Thursday. Centessa Pharmaceuticals has a 52-week low of $7.75 and a 52-week high of $19.09. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. The company has a market capitalization of $2.21 billion, a P/E ratio of -10.96 and a beta of 1.54. The company has a 50-day simple moving average of $16.46 and a 200 day simple moving average of $16.36.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.